Ceribell is focused on making EEG widely available, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The Ceribell EEG System received FDA 510(k) clearance in 2017 and is commercially available in the United States.
Market
Medical Devices
Location
Mountain View,
California,
United States
Coinvestors
LivaNova, Optimas Capital Partners Fund, The Rise Fund, UC